Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ASMT/CYP1A1 molecular signature in predicting clinical prognosis or immune characteristics of solid tumors

A technology of CYP1A1 and entities, which is applied in the field of application of ASMT/CYP1A1 molecular tags in predicting the clinical prognosis or immune characteristics of solid tumors, can solve the problems of no molecular tags, etc., and achieve the effect of improving the therapeutic effect

Active Publication Date: 2021-12-28
SUN YAT SEN UNIV CANCER CENT
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are currently no molecular tags for relevant applications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ASMT/CYP1A1 molecular signature in predicting clinical prognosis or immune characteristics of solid tumors
  • Application of ASMT/CYP1A1 molecular signature in predicting clinical prognosis or immune characteristics of solid tumors
  • Application of ASMT/CYP1A1 molecular signature in predicting clinical prognosis or immune characteristics of solid tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] The present invention will be further described below in conjunction with specific experiments. It should be understood that the following content is only used to illustrate the present invention and is not intended to limit the protection scope of the present invention.

[0022] ASMT / CYP1A1 ratio in different solid tumors

[0023] By analyzing 14 solid tumors (bladder cancer, breast cancer, cervical cancer, colon cancer, head and neck squamous cell carcinoma, kidney cancer, hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic cancer, prostate cancer, skin cancer) in the public database TCGA , gastric cancer and thyroid cancer) transcriptome and genome data of 6,658 tumor samples, and calculate the ratio of ASMT to CYP1A1 in each tumor tissue (ASMT / CYP1A1), which reflects the level of melatonin in the tumor tissue. The ASMT / CYP1A1 results of each tumor tissue were divided into High Index and Low Index ( figure 1 )Group.

[0024] Rela...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of the ASMT / CYP1A1 molecular signature in predicting the clinical prognosis or immune characteristics of solid tumors. The inventors studied the transcriptome and genome data of 6,658 tumor samples from 14 kinds of solid tumors, and conducted a large-scale bioinformatics analysis, confirming that the ratio of ASMT / CYP1A1 in different solid tumors is related to the clinical prognosis and tumor mutation level of patients. , Tumor neoantigen load relationship. Among them, the clinical prognosis of cervical cancer, gastric cancer, and melanin patients in the High Index group was more impressive. The results of multivariate analysis showed that ASMT / CYP1A1 was an independent predictor of clinical prognosis in cancer patients; in addition, in colorectal cancer, head and neck squamous Among patients with cancer, kidney cancer, liver cancer, prostate cancer, and melanoma, although the prognosis of patients in the Low Index group is poor, there are more mutation loads and / or tumor neoantigens, suggesting that patients in this group are more likely to benefit from immunotherapy. benefit.

Description

technical field [0001] The present invention relates to markers and applications for predicting clinical prognosis of solid tumors, immune body mutation level and / or neoantigen load. Background technique [0002] Tumor is the third major disease threatening human health. In 2018, there were about 18.19 million new cancer cases and 9.6 million cancer deaths worldwide. The incidence of tumors has shown a downward trend year by year with the advancement of medical technology and the enhancement of people's awareness of cancer prevention, while the mortality rate of some cancers is still high. Therefore, it is very important to accurately evaluate the prognosis of tumor patients and choose the appropriate treatment plan according to their characteristics. In recent years, immunotherapy has developed rapidly and has become the fourth major anti-cancer weapon after surgery, radiotherapy and chemotherapy, and targeted therapy. Relevant immunotherapy drugs, such as anti-PD-1 mono...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886
CPCC12Q1/6886C12Q2600/118C12Q2600/158
Inventor 孙颖吕佳蔚陈雨沛郑子奇
Owner SUN YAT SEN UNIV CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com